BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Post by GObabyGO1on Jan 07, 2011 6:05pm

502 Views

Post# 17941587

next week

Things looking great going into next week. Im really convinced that there is more here then a pump and dump. This would be perfect timing for an update on NRM8499. The study was expected to conclude in the second half of 2010 as per their website. Very excited to see where this takes us next week. GLTA

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023